Here are the DEF 14A proxy statements from Eli Lilly and Company (LLY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LLY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LLY filings page.
Eli Lilly and Company is asking shareholders to vote on directors, executive pay, auditor ratification, and key governance changes at its 2026 virtual annual meeting. Management seeks approval to declassify the board, remove supermajority voting provisions, and opposes shareholder proposals on an independent chair and expanded lobbying disclosure.
The proxy highlights 2025 revenue of $65.2 billion, reported EPS of $22.95 and non-GAAP EPS of $24.21, along with a 40% 2025 total shareholder return that exceeded the S&P 500 and a peer group over one-, three-, and five-year periods. Incentive plans paid above target, with a 218% annual bonus payout and 200% payouts on three-year shareholder value and relative value awards, reflecting strong stock performance.